Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Emory University
28 participants
Nov 9, 2023
INTERVENTIONAL
Conditions
Summary
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.
Eligibility
Inclusion Criteria5
- Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
- Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- There will be no limitations on number of prior lines of therapy
- Trial is open to non-English speaking patients
- Trial is open to patients referred from community practice
Exclusion Criteria4
- Patients who are \< 18 years old
- Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
- Patients who are incarcerated
- Patients who are unable to provide consent / lack decision-making capacity
Interventions
Given PO
Undergo biopsy
Undergo CT
Undergo paracentesis
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05998135